Mainstreamed genetic testing for women with ovarian cancer: first-year experience

Abstract

MGT appears to be a feasible way of providing <i>BRCA</i> testing to patients with ovarian cancer. Greater clarity of how oncologists use VUS results is needed, as well as further research on psychosocial implications of MGT for patients with ovarian cancer, which may include somatic testing in the future.